Sinovac Biotech (SVA) Stock News

SINOVAC Biotech's Board announced significant dividend updates and shareholder value initiatives. The company will accelerate payment of a previously announced $55.00 per share special dividend, expected around July 7, 2025. Additionally, a second special dividend of $19.00 per share will be declared after the Special Shareholder Meeting (SSM), with potential for an extra $3.73 if PIPE shares are cancelled. The Board adopted a new dividend policy promising regular distributions between $20.00-$50.00 per share from surplus cash. These actions aim to compensate shareholders who were previously excluded from over $2 billion in subsidiary-level distributions. The company also committed to holding an annual meeting in Q2 2026 and is exploring potential listing on the Hong Kong Stock Exchange. These moves come amid ongoing conflicts with a Dissenting Investor Group led by Advantech/Prime Success and Vivo Capital.

Prime Success LP, owning 8% of Sinovac Biotech (NASDAQ: SVA), issued a statement addressing alleged false claims by the current board regarding the July 8, 2025 Special Meeting. The statement refutes several accusations, including claims about dividend blocking and new lawsuits. Prime Success clarifies their injunction only seeks to protect their shareholder rights and maintain status quo, not prevent dividend distribution. They argue the current '1Globe Activist Board' is weaponizing dividends by setting the record date after the Special Meeting and has breached fiduciary duties through misleading statements and misuse of company resources. Prime Success supports SAIF Partners' nominees for the board and urges shareholders to vote using the GOLD proxy card.

SAIF Partners, owning 15% of Sinovac Biotech (SVA), has filed definitive proxy materials and nominated ten director candidates for election at a special shareholders meeting on July 8, 2025. The firm aims to address critical issues at Sinovac, including the distribution of billions in retained cash, resuming stock trading after a six-year halt, and resolving ongoing shareholder disputes. SAIF criticizes the current board's ineffective leadership and lack of strategic direction, noting that only one board member isn't affiliated with 1Globe and OrbiMed, who hold 9.5% and 3.8% ownership respectively. The proposed nominees represent major shareholders including CEO Weidong Yin, SAIF Partners, Vivo Capital, CDH Investment, Advantech Capital, and 1Globe. SAIF argues that new leadership is essential to end costly legal battles and implement proper corporate governance.

Heng Ren Silk Road Investments LLC, a shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA), has issued an open resolution urging the company to pay the declared $55 special cash dividend before the July 8 board election, specifically suggesting July 7 as the payment date. The resolution aims to remove uncertainty surrounding the dividend payment, which was originally scheduled for 'on or about' July 9. Heng Ren argues that paying the dividend before the board vote would eliminate concerns about a new board potentially canceling the dividend and allow shareholders to focus on evaluating board candidates' qualifications. The investment firm plans to host a webinar to discuss the voting process and related issues with shareholders.

SINOVAC Biotech (NASDAQ: SVA) has disclosed that Advantech/Prime Success filed a Petition for Emergency Injunctive Relief that could prevent the scheduled US$55.00 special dividend payment to shareholders on July 9, 2025. Vivo Capital has also challenged the dividend distribution, requesting the paying agent to withdraw from facilitating the payment. The SINOVAC Board strongly opposes these actions, noting that the Dissenting Investor Group (Advantech and Vivo Capital) has already received over US$1.1 billion in dividends from SINOVAC's operating subsidiary. The Board has set aside funds in escrow for potential 2018 PIPE shares payments pending legal resolution. SINOVAC plans to file an Opposition Brief and expects a hearing on June 18, with a decision anticipated by Friday.

Prime Success (8% shareholder) responds to Sinovac Biotech's (SVA) claims regarding the July 8, 2025 Special Meeting. The letter criticizes the current '1Globe Activist Board' for misleading statements and questionable practices. Prime Success highlights their past contributions, including critical investments that enabled CoronaVac development, which delivered billions of doses to 60+ countries. They support SAIF Partners' proposed board slate, which includes representatives from all 5%+ shareholders. Key contentions include the timing of dividend distribution (scheduled one day after the meeting) and the board's focus on litigation over company growth. Prime Success urges shareholders to consider the company's future direction and wait for SAIF's proxy materials before voting.

SINOVAC Biotech's Board issued a critical letter to shareholders regarding an upcoming Special Meeting on July 9, 2025, where shareholders will vote on an attempt by the Dissenting Investor Group to remove the current board. The letter outlines how Prime Success and Vivo Capital acquired shares through an invalid PIPE transaction authorized by an "Imposter Board" that was deemed illegitimate by the UK Privy Council. The current board, reconstituted in February 2025, has announced a $55 per share special dividend and plans an additional $11 per share redistribution upon cancellation of unauthorized PIPE shares. The board warns that the Dissenting Investor Group previously distributed $2 billion in dividends to themselves while valid shareholders received nothing, and attempted to buy out SINOVAC at $7 per share. The letter emphasizes the board's commitment to restoring shareholder value, resuming NASDAQ trading, and ensuring fair treatment of all shareholders.

Vivo Capital, an 8% stakeholder in Sinovac Biotech (NASDAQ:SVA), issued a letter addressing what they claim are false statements from Sinovac's Board. The dispute centers on corporate governance issues, including contested Board composition and dividend distribution. Key issues include the resignation of Grant Thornton Zhitong as independent auditor, delayed SEC filings, and NASDAQ compliance concerns. Vivo defends its PIPE investment and convertible bond contributions, which were crucial for CoronaVac vaccine development. The firm highlights its $24M support to Sinovac Life Sciences, plus a $7.5M convertible bond investment, and facilitation of $527M additional capital. The letter precedes a July 8, 2025 special shareholder meeting for Board elections, with Vivo claiming the current Board is attempting to illegally exclude certain shareholders from participating.

Prime Success LP, owning 8% of Sinovac Biotech (NASDAQ: SVA), has issued a letter to shareholders regarding the July 8, 2025 Special Meeting, advocating for change in the Board of Directors. The letter supports SAIF Partners' slate of director nominees, who commit to: distributing a $55/share dividend and future dividends fairly, reinstating NASDAQ trading, improving corporate governance, and fostering sustainable growth. Prime Success criticizes the current Board for causing trading halts since 2019, impeding dividend distributions, engaging in wasteful litigation, attempting questionable dividend schemes, and creating operational uncertainty leading to the external auditor's resignation. The management team has publicly called for new Board elections, highlighting the severity of internal conflicts.